Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 19/20 | 0.74 |
| ▸ | NQO1 | P15559 | 16/20 | 0.74 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18059760 | 0.99 | NQO2 (0.73) | NQO2NQO1MITF | |
| SCHEMBL18059753 | 0.86 | NQO2 (0.74) | NQO2NQO1MITF | |
| Hydrochloric Acid SCHEMBL20711060 | 0.85 | NQO2 (0.72) | NQO2NQO1MITF | |
| Temacrazine SCHEMBL14259457 | 0.82 | NQO2 (0.76) | NQO2NQO1MITF | |
| SCHEMBL8958309 | 0.79 | NQO2 (0.69) | NQO2NQO1 | |
| SCHEMBL9024299 | 0.78 | NQO2 (0.49) | NQO2NQO1 | |
| SCHEMBL13928512 | 0.77 | NQO2 (0.76) | NQO2NQO1 | |
| SCHEMBL9024179 | 0.75 | NQO2 (0.48) | NQO2NQO1 | |
| SCHEMBL14259715 | 0.74 | NQO2 (0.62) | NQO2NQO1MITF | |
| Hydrochloric Acid SCHEMBL18059764 | 0.74 | NQO2 (0.68) | NQO2NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202349-B2 | Asymmetric bis-acridines with antitumour activity and their uses | Gdansk University of Technology (PL) | 2019-02-12 | — | — | US | disclosed |
| US-20180086712-A1 | ASYMMETRIC BIS-ACRIDINES WITH ANTITUMOUR ACTIVITY AND THEIR USES | Gdansk University of Technology (PL) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202349-B2 | Asymmetric bis-acridines with antitumour activity and their uses | MCL1, BAD, ACR | NQO2 942/4885NQO1 641/4885MITF 1638/4885 |
| US-20180086712-A1 | ASYMMETRIC BIS-ACRIDINES WITH ANTITUMOUR ACTIVITY AND THEIR USES | MCL1, ACR, BAD | NQO2 983/4885NQO1 798/4885MITF 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.